

Dear Healthcare Professional,

**Re: Discontinuation of supply of Vivaxim® (*Salmonella typhi* Vi polysaccharide & hepatitis A virus antigen) vaccine**

We are writing to inform you that Vivaxim® (*Salmonella typhi* Vi polysaccharide and hepatitis A virus antigen) vaccine (AUST R 82745, TT50-6820) will no longer be supplied in Australia and New Zealand once current stocks have depleted. The last batches manufactured have an expiry date of 30<sup>th</sup> November 2024.

After careful consideration, we've made the decision to no longer offer Vivaxim® globally. Our decision to stop the production of Vivaxim® is not linked to safety or quality issues. Our focus is always on providing you with the best products and experiences, and we appreciate your understanding as we evolve our offerings.

Sanofi has single-antigen vaccines that are available as alternatives to Vivaxim® including:

- **AVAXIM®**, Hepatitis A virus (inactivated, adsorbed) for immunisation against hepatitis A, and
- **TYPHIM Vi®**, *Salmonella typhi* Vi polysaccharide vaccine for immunisation against typhoid fever

Both Avaxim and Typhim Vi are indicated for adults and children 2 years and older

For further details on these products, please refer to our product information through below link

For Australia <https://medsinfo.com.au/>

For New Zealand <https://www.medsafe.govt.nz/Medicines/infoSearch.asp>

These products are not listed on the PBS or NIP

If you would have any questions or concerns, please feel free to contact us:

- For medical enquiries **Sanofi Medical Information 1800 818 806**
- For enquiries relating to supply **Customer Service 1800 829 468**

We apologise for any inconvenience caused.

Yours sincerely,



Regis Launay  
General Manager ANZ, Vaccines  
Sanofi